Dimethyl Sulfoxide / selectivity Cancer Research Results

DMSO, Dimethyl Sulfoxide: Click to Expand ⟱
Features:
Chemical that dissolves many substances that can affect the body.
It is used for bladder inflammation, limb pain, and IV leakage, but it can also cause side effects and interact with other drugs.

Dimethyl sulfoxide — DMSO is a small, highly polar organosulfur compound with the formula (CH3)2SO. It is formally classified as a polar aprotic solvent, membrane-permeability enhancer, cryoprotectant and pharmaceutical excipient; concentrated DMSO also has direct biological activity. Standard abbreviations are DMSO and Me2SO. Commercial DMSO is produced by oxidation of dimethyl sulfide, historically obtained as a kraft-pulping by-product. In cancer research, DMSO is primarily a solvent and experimental differentiation agent rather than a clinically established anticancer drug. Its biological effects are strongly concentration-, exposure-time-, cell-type- and formulation-dependent.

Primary mechanisms (ranked):

  1. Concentration-dependent alteration of lipid-bilayer organization, membrane fluidity and permeability, including transient aqueous pore formation at sufficiently high concentrations.
  2. Induction of terminal differentiation and reversible growth arrest in selected malignant hematopoietic and transformed cell models.
  3. Modulation of gene expression, chromatin organization and transcriptional programs associated with differentiation and tumour-suppressive phenotypes.
  4. Direct cytotoxicity at higher concentrations through membrane injury, mitochondrial dysfunction, caspase activation, apoptosis or inflammatory cell-death signalling.
  5. Hydroxyl-radical scavenging and suppression of some oxidative and inflammatory injury pathways; these effects may protect normal or malignant cells from oxidative therapies.
  6. Enhancement of transdermal and cellular delivery of co-administered compounds, creating substantial drug-interaction and experimental-confounding potential.
  7. DMSO penetrates human skin with little effect on tissues; and the solvent was tested as a way for medicines to be carried into the body as an alternative to oral formulations or injectables.

Bioavailability / PK relevance: DMSO is rapidly absorbed across skin and biological membranes and distributes widely into tissues and body fluids. It is metabolized primarily to dimethyl sulfone and dimethyl sulfide; metabolites are eliminated through urine, feces, breath and skin. Systemic exposure can produce a characteristic garlic-like taste and odour. DMSO also increases tissue penetration of other chemicals, so pharmaceutical purity and control of contaminants are critical.

In-vitro vs systemic exposure relevance: Most cancer differentiation, growth-arrest and cytotoxicity studies use approximately 0.5–2.5% DMSO, equivalent to roughly 70–350 mM. These sustained concentrations are generally not representative of safe systemic anticancer exposure. DMSO concentrations routinely treated as an inert vehicle can themselves alter membranes, transcription, metabolism, proliferation and drug responses; solvent controls must therefore use the lowest feasible concentration, commonly at or below 0.1%, with cell-specific validation.

Clinical evidence status: Cancer evidence is predominantly preclinical and includes older leukemia-differentiation models and diverse cell-culture observations. DMSO has no established role as systemic or topical anticancer monotherapy and is not supported by anticancer RCT evidence. Its clinically recognized roles are intravesical symptomatic treatment of interstitial cystitis, cryopreservation of cells and tissues, and use as a penetration-enhancing pharmaceutical excipient. In oncology it is more relevant as a solvent, delivery vehicle, cryoprotectant and potential modifier of treatment response than as an active anticancer therapy.



Mechanistic effects of dimethyl sulfoxide

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Lipid bilayer permeability and fluidity ↑ membrane fluidity and permeability; ↑ pore formation (dose-dependent) ↑ membrane fluidity and permeability; membrane disruption at high concentration P Changes membrane organization and transport Central physicochemical mechanism. Low concentrations produce subtle bilayer changes; higher concentrations can cause dehydration, thinning and transient aqueous defects.
2 Malignant cell differentiation ↑ terminal differentiation in HL-60, Friend erythroleukemia and selected other models Context-dependent differentiation effects G Reduces immature malignant phenotype Classical but model-specific effect, usually requiring prolonged exposure to approximately 1–2% DMSO. Not clinically validated as leukemia differentiation therapy.
3 Cell-cycle progression ↓ G1 to S progression; ↑ reversible G1 arrest (context-dependent) ↓ proliferation at elevated concentrations G Cytostatic growth suppression Often accompanies differentiation. Arrest may be reversible after DMSO removal and should not automatically be classified as tumour-cell killing.
4 Transcription and chromatin state ↑ differentiation-associated transcription; ↓ oncogenic phenotype in selected models Broad gene-expression changes (model-dependent) G Reprograms cell phenotype DMSO is not a selective epigenetic drug. Effects include changes in chromatin conformation, transcription factors and tumour-suppressive genes such as HLJ1 in specific models.
5 Apoptosis and inflammatory cell death ↑ apoptosis or caspase activation (high concentration only); ↓ apoptosis in some models ↑ cytotoxicity and caspase-1 activation (high concentration only) R–G Concentration-dependent cell death or cytoprotection Direction is not uniform. Approximately 2.5% DMSO induced apoptosis selectively in one transformed keratinocyte model, whereas other studies found suppression of apoptosis.
6 Mitochondrial integrity ↓ mitochondrial function at cytotoxic concentrations; preservation reported under some oxidative injuries ↔ or ↑ mitochondrial preservation at low protective exposures; ↓ function at high concentration R–G Bidirectional mitochondrial modulation Secondary and highly context-dependent. DMSO may either contribute to cytotoxicity or protect mitochondria from specific oxidants.
7 Hydroxyl radical and oxidative injury ↓ hydroxyl-radical-mediated damage; possible ↓ efficacy of ROS-dependent therapy ↓ oxidative tissue injury P–R Radical scavenging and cytoprotection DMSO is widely used experimentally as a hydroxyl-radical scavenger. This is not equivalent to broad antioxidant activity against every ROS species.
8 Radiosensitization and radioprotection ↓ radiation injury in some systems; mixed effects on treatment response ↓ hydroxyl-radical-mediated radiation injury P–R Predominantly radioprotective under radical-mediated conditions DMSO should not be classified generally as a radiosensitizer. Radical scavenging can protect both normal and malignant cells and may confound radiation experiments.
9 Drug and solute penetration ↑ intracellular and transmembrane delivery of dissolved agents ↑ dermal and tissue uptake of drugs and contaminants P Delivery enhancement Can increase apparent potency, toxicity or distribution of co-administered compounds. DMSO vehicle controls do not isolate this interaction when permeability itself changes.
10 Cryoprotection ↑ post-thaw viability of tumour cells and cellular therapeutics ↑ post-thaw viability; ↓ ice-crystal injury P Prevents freezing-associated cellular damage Major clinical and laboratory use. Residual DMSO in infused cryopreserved products can produce acute infusion reactions and other toxicity.
11 Clinical Translation Constraint In-vitro active concentrations often exceed practical systemic anticancer exposure Systemic, ocular, hypersensitivity and interaction concerns G Limits anticancer translation No established anticancer indication. Biological activity is nonselective, concentration-dependent and inseparable from solvent, membrane and delivery effects.

P: 0–30 min    R: 30 min–3 hr    G: >3 hr
selectivity, selectivity: Click to Expand ⟱
Source:
Type:
The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues.

Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance

Factors that affect selectivity:
1. Ability of Cancer cells to preferentially absorb a product/drug
-EPR-enhanced permeability and retention of cancer cells
-nanoparticle formations/carriers may target cancer cells over normal cells
-Liposomal formations. Also negatively/positively charged affects absorbtion

2. Product/drug effect may be different for normal vs cancer cells
- hypoxia
- transition metal content levels (iron/copper) change probability of fenton reaction.
- pH levels
- antiOxidant levels and defense levels

3. Bio-availability
Scientific Papers found: Click to Expand⟱
6726- DMSO,    DMSO induces apoptosis in SV40-transformed human keratinocytes, but not in normal keratinocytes
- in-vitro, NA, NA
Apoptosis↑, selectivity↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

selectivity↑, 1,  
Total Targets: 2

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: selectivity, selectivity
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:72  Target#:1110  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page